Please note that the details of this Challenge are no longer open. This challenge is under evaluation and is no longer accepting new submissions. You can:
Challenge <p>Servier Challenge: Looking for Partners to Explore Novel Opportunities in Neurodegenerative Diseases</p>

Servier Challenge: Looking for Partners to Explore Novel Opportunities in Neurodegenerative Diseases

Award:  varies
STATUS: Under Eval
Active Solvers: 166
Posted: Nov 20 2017
Challenge ID: 9934026
 
Team Project Rooms are available on this Challenge. Team Share Challenge Share
Abstract

Servier, a middle size international pharmaceutical company based in France,  is looking for partners to find and develop novel, early-stage opportunities – ranging from exploratory projects with validated targets to lead optimization – in the area of Alzheimer’s and Parkinson’s disease. The goal is to establish mid to long-term collaborations in which Servier offers scientific inputs, technological help and financial support for co-development of the innovative projects.

This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.

Overview

Servier is interested in the continuous development of knowledge and new medicines, and advancing therapeutics to serve patients. One key area of interest is in neurodegenerative disorders (including Alzheimer’s, Parkinson’s disease) related to the aggregation and misfolding of the proteins tau, amyloid β, and α-synuclein.

Servier understands that drug discovery in the neurodegenerative diseases field is a highly complex and risky endeavor, hence it is strongly believed that collaborative efforts are the path forward to increase success and deliver highly needed innovative therapies to patients. With that in mind, Servier is looking for partners to find and develop novel, early-stage opportunities – ranging from exploratory projects with validated targets to lead optimization – in the area of Alzheimer’s and Parkinson’s disease. The goal is to establish mid to long-term collaborations in which Servier envisages to offer scientific inputs, technological help and financial support for co-development of the innovative projects.

This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (about 2-5 pages, including supporting non-confidential information and contact details) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, the Seeker may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed upon time frame.

NOTE: Only proposals from Solvers who have the ability to work as the collaboration partner will be considered.

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on January 19, 2018.

Late submissions will not be considered.

ABOUT THE SEEKER

We are an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.

Operating in 148 countries, we have 21,000 collaborators employed worldwide and a turnover of 4 billion euros in 2016. Entirely independent, we are able to reinvest 25% of our total revenue (excluding generics) into Research and Development, and all profits are used for further development.

Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, oncology and diabetes. We are a leading force in cardiology—number 2 in Europe, number 8 worldwide—and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs.

Our three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 15 production centres around the world. We have an active partnership policy in the field of biotechnology and we are investing in e-health through our internal WeHealth by Servier initiative.

All our employees are driven by shared values and guided by a common vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress to serve patient needs.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is an eRFP Challenge?

eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.

After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.

This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.

Share This Challenge
InnoCentive Trust Partners